The relevant disclosure is attached.

Fortis Healthcare Limited Tower-A, Unitech Business Park, Block-F, South City 1, Sector – 41, Gurgaon, Haryana – 122 001 (India) Tel 0124 492 1033 Fax 0124 492 1041 Emergency 105010 Email: secretarial@fortishealthcare.com Website : www.fortishealthcare.com August 06, 2026 FHL/SEC/2026-27 The National Stock Exchange of India Ltd. BSE Limited Scrip Symbol: FORTIS Scrip Code: 532843 Sub: Earnings Presentation under Regulation 30 SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 Dear Madam/Sir, Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find enclosed herewith the ‘Earning Presentation’ for the quarter ended June 30, 2026. The date and time of occurrence of event is Thursday, August 06, 2026 at 6:45 Hours (IST). This is for your information and records. Thanking you, Yours Sincerely, For Fortis Healthcare Limited Satyendra Chauhan Company Secretary & Compliance Officer M. No. - A14783 Encl : As stated above FORTIS HEALTHCARE LIMITED Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 Tel :0172-4692222, Fax : 0172-5096221, CIN : L85110PB1996PLC045933 FORTIS HEALTHCARE LIMITED EARNINGS PRESENTATION – Q1 FY27 August 06, 2026 DISCLAIMER Thispresentationmaynotbecopied,published,distributedortransmitted.Thepresentationhasbeenpreparedsolelybythecompany. Any reference in this presentation to “Fortis Healthcare Limited” shall mean, collectively, the Company and its subsidiaries. This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus, offering circular or offering memorandum and is notan offerorinvitation tobuyorsell anysecurities,norshall part,orall,of this presentationform the basis of,orbe relied onin connection with,any contract or investment decision in relation to any securities. Furthermore, this presentation is not and should not be construed as an offer or a solicitationofanoffertobuysecuritiesofthecompanyforsaleintheUnitedStates,Indiaoranyotherjurisdiction. Securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering in the United States may be made only bymeans of an offering document thatmay be obtained from the Company and that will contain detailed information about the Company and its management, as well as financial statements. Any offer or sale of securities in a given jurisdiction is subject to the applicable lawsofthatjurisdiction. Thispresentationcontainsforward-lookingstatementsbasedonthecurrentlyheldbeliefsandassumptionsofthemanagementoftheCompany, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks,uncertaintiesandotherfactors,recipientsofthispresentationarecautionednottoplaceunduerelianceontheseforward-lookingstatements. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this presentation, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any personofsuchrevisionorchanges. By attending or assessing this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential futureperformanceofthebusinessoftheCompany. Neither the delivery of this presentation nor anyfurther discussions of the Company with any of the recipients shall, under any circumstances, create anyimplicationthattherehasbeennochangeintheaffairsoftheCompanysincethatdate. About Fortis Healthcare National Capital Region ➢ FMRI, Gurugram 36 Healthcare Facilities ➢ FEHI, New Delhi ➢ Shalimar Bagh ➢ Noida 2,191 Himachal Pradesh ➢ Vasant Kunj (O&M) 6,150+ Operational Beds^ ➢ Faridabad ➢ Kangra 81 Punjab ➢ Manesar, Gurugram ➢ La Femme GK ➢ Mohali ➢ Def Col 8,100+ Doctors ➢ Ludhiana 989 ➢ C-DOC (O&M) ➢ Ludhiana 2 ➢ Greater Noida ➢ Amritsar ➢ Adayu ➢ Jalandhar 9,500+ Nurses# Rajasthan ➢ Jaipur 275 385 West Bengal 28,500+ employees Kolkata (including Agilus) ➢ Anandpur Maharashtra ➢ FHKI & FMC Chhattisgarh ➢ Mulund 768 ➢ Vashi ➢ Raigarh (O&M) 70 ➢ Kalyan Telangana ➢ SL Raheja (O&M) Hyderabad 4 JCI Accredited Karnataka ➢ Lakdi-Ka-Pul(O&M) 271 ➢ L.B. Nagar (O&M) Bengaluru ➢ BG Road Tamil Nadu 888 ➢ CG Road 241 Chennai 34 NABH Accredited/ ➢ NagarBhavi Certified ➢ Perumbakkam–Sholinganallur (O&M) ➢ Rajaji Nagar ➢ Yeshwanthpur ➢ Kengeri(O&M) Beds ➢ Richmond Road (O&M) Note: ^Including ~1,200 O&M beds 3 # Including trainee nurses AGENDA 1. Performance Highlights • Earnings and Financial Summary – Q1FY27 2. Performance Review - Hospital Business 3. Performance Review - Diagnostics Business 4. Clinical Excellence at Fortis 5. Appendix Q1FY27 PERFORMANCE HIGHLIGHTS Q1FY27 SNAPSHOT Consolidated Revenue Consolidated Op EBITDA1 Consolidated PBT2 2,545 Crores 568 Crores 354 Crores (22.3% Margin) 17.5% 15.8% 4.6% Net Debt / (Cash)4 Net Debt to EBITDA3,4 Consolidated PAT2 263 Crores 2,233 Crores 1.01x vs 0.92x 3.6% 1. Excluding ESOP expenses of ~INR 31Cr. 2. Excluding exceptional items 3. Basis Q1 annualized EBITDA 4. Net Debt as on 30th June 2026 Q1FY27 SNAPSHOT ➢ Hospital business revenues grew 19% to INR 2,187 Cr versus INR 1,838 Cr in Q1FY26 ➢ Hospital Business Operating EBITDA* stood at INR 471 Cr, up 15.9%; while operating margin was at 21.5% versus 22.1% in Q1FY26. On a like-for-like basis, excluding the impact of the newly acquired / commissioned facilities, the Operating EBITDA margin* in Q1FY27 was ~22%, similar to Q1FY26. ➢ Q1FY27 hospital business ARPOB was at INR 2.71 Cr per annum vs INR 2.64 Cr in Q1FY26, up 2.6% ➢ Occupancy for the quarter stood at 68.7% versus 69.0% in Q1FY26 ➢ The company’s diagnostics business reported gross revenues of INR 407 Cr versus INR 369 Cr in Q1FY26 growing by 10.2%. ➢ Operating EBITDA Margin* of the diagnostics business (basis gross revenues) stood at 23.9% versus 23.0% in Q1FY26 *Excluding ESOP expenses of ~INR 31 Cr. Including the ESOP expenses the Operating EBITDA margin stood at 20.1% for Hospital business and 23.8% for Diagnostics business 7 CONSOLIDATED EARNINGS SUMMARY – Q1FY27 All figures in INR Cr Revenue Op EBITDA & Margin 2,545 2,365 568 2,167 22.3% 22.5% 22.6% Q1FY26 Q4FY26 Q1FY27 Q1FY26 Q4FY26 Q1FY27^ Up 17.5% Up 15.8% PBT before Exceptional Items PAT* 254 263 338 337 Q1FY26 Q4FY26 Q1FY27 Q1FY26 Q4FY26 Q1FY27 Up 4.6% Up 3.6% ^ Q1FY27 Operating EBITDA and margin excludes ESOP expenses of ~INR 31 Cr * Q1FY27 and Q1FY26 PAT excludes exceptional gain of INR 9.5 Cr and INR 12.6 Cr respectively, which pertains primarily to reversal of impairment in an associate Company * Q4FY26 PAT excludes exceptional loss of INR 12.5 Cr which pertains primarily to the impairment of investment in an associate Company 8 CONSOLIDATED EARNINGS SUMMARY All figures in INR Cr Consolidated Revenue 2,545 2,365 2,331 2,265 2,167 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Op EBITDA Margin Op EBITDA PBT (before Exceptional items) 23.9% 22.3% 22.5% 22.3% 22.6% 556 568 491 505 338 337 354 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27^ ^ Q1FY27 Operating EBITDA and margin excludes ESOP expenses of ~INR 31 Cr 9 Q1FY2 [Showing first 8,000 characters — download PDF for full document]